Virtual Reality Treatments Can Alleviate Fear of Heights

This article originally appeared here.
Share this content:
Virtual Reality Treatments Can Alleviate Fear of Heights
Virtual Reality Treatments Can Alleviate Fear of Heights

THURSDAY, July 12, 2018 (HealthDay News) -- Automated virtual reality (VR) treatments can alleviate fear of heights, according to a study published online July 11 in The Lancet Psychiatry.

Daniel Freeman, Ph.D., from the University of Oxford in the United Kingdom, and colleagues conducted a randomized trial of automated VR versus usual care in adults aged older than 18 years with a fear of heights. One hundred participants were randomized to either automated VR delivery in roughly six 30-minute sessions administered two to three times per week over a two-week period (49 participants) or to usual care (51 participants). Three fear-of-height assessments were conducted at baseline, end of treatment (two weeks), and follow-up (four weeks).

The researchers found that the VR treatment reduced fear of heights at the end of treatment compared with the control groups (mean change score on the Heights Interpretation Questionnaire: −24.5 versus −1.2; adjusted difference, −24.0). The benefit was maintained at follow-up (mean change score, −25.1 versus −1.5; adjusted difference, −24.3). To at least halve the fear of heights, the number needed to treat was 1.3; there were no reports of adverse events.

"Psychological therapy delivered automatically by a VR coach can produce large clinical benefits," the authors write. "Evidence-based VR treatments have the potential to greatly increase treatment provision for mental health disorders."

Several authors disclosed financial ties to Oxford VR and Virtual Bodyworks. Oxford VR contributed funding to the study.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »